Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2014 (2014), Article ID 674690, 10 pages
http://dx.doi.org/10.1155/2014/674690
Research Article

BL153 Partially Prevents High-Fat Diet Induced Liver Damage Probably via Inhibition of Lipid Accumulation, Inflammation, and Oxidative Stress

1College of Bioengineering, Chongqing University, Chongqing 400044, China
2The Chinese-American Research Institute for Diabetic Complications, School of Pharmaceutical Sciences & Key Laboratory of Biotechnology Pharmaceutical Engineering, Wenzhou Medical University, Wenzhou 325035, China
3Department of Pediatrics of the University of Louisville, The Kosair Children’s Hospital Research Institute, Louisville, KY 20202, USA
4Rui’an Center of the Chinese-American Research Institute for Diabetic Complications, The Third Affiliated Hospital of the Wenzhou Medical University, Wenzhou 325200, China
5Department of Cardiology at the First Hospital & School of Public Health, Jilin University, Changchun 130021, China
6Bioland Biotec Co., Ltd., Zhangjiang Modern Medical Device Park, Pudong, Shanghai 201201, China
7Bioland R&D Center, 59 Songjeongni 2-gil, Byeongcheon, Dongnam, Cheonan, Chungnam 330-863, Republic of Korea

Received 9 December 2013; Accepted 20 February 2014; Published 3 April 2014

Academic Editor: Si Jin

Copyright © 2014 Jian Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Poirier, “Targeting abdominal obesity in cardiology: can we be effective?” The Canadian Journal of Cardiology, vol. 24, supplement D, pp. 13D–17D, 2008. View at Google Scholar · View at Scopus
  2. C. L. Ogden, S. Z. Yanovski, M. D. Carroll, and K. M. Flegal, “The epidemiology of obesity,” Gastroenterology, vol. 132, no. 6, pp. 2087–2102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Lin, Z. Zhou, Y. Liu et al., “Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese,” PLoS ONE, vol. 6, no. 4, Article ID e18398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. G. C. Farrell and C. Z. Larter, “Nonalcoholic fatty liver disease: from steatosis to cirrhosis,” Hepatology, vol. 43, supplement 1, no. 2, pp. S99–S112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. L. A. Adams, J. F. Lymp, J. St. Sauver et al., “The natural history of nonalcoholic fatty liver disease: a population-based cohort study,” Gastroenterology, vol. 129, no. 1, pp. 113–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. K. Dowman, J. W. Tomlinson, and P. N. Newsome, “Pathogenesis of non-alcoholic fatty liver disease,” QJM, vol. 103, no. 2, pp. 71–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. F. Tacer and D. Rozman, “Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation,” Journal of Lipids, vol. 2011, Article ID 783976, 14 pages, 2011. View at Publisher · View at Google Scholar
  8. C. P. Day and O. F. W. James, “Steatohepatitis: a tale of two “hits”?” Gastroenterology, vol. 114, no. 4, pp. 842–845, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Kuribara, E. Kishi, N. Hattori, M. Okada, and Y. Maruyama, “The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark,” Journal of Pharmacy and Pharmacology, vol. 52, no. 11, pp. 1425–1429, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Li, C. Xu, Q. Zhang, J. Y. Liu, and R. X. Tan, “In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases,” Journal of Ethnopharmacology, vol. 98, no. 3, pp. 329–333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. V. K. Bajpai, J. I. Yoon, and S. C. Kang, “Antioxidant and antidermatophytic activities of essential oil and extracts of Magnolia liliflora Desr,” Food and Chemical Toxicology, vol. 47, no. 10, pp. 2606–2612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Dikalov, T. Losik, and J. L. Arbiser, “Honokiol is a potent scavenger of superoxide and peroxyl radicals,” Biochemical Pharmacology, vol. 76, no. 5, pp. 589–596, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Ock, H. S. Han, S. H. Hong et al., “Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation,” British Journal of Pharmacology, vol. 159, no. 8, pp. 1646–1662, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. Y.-R. Lin, H.-H. Chen, C.-H. Ko, and M.-H. Chan, “Effects of honokiol and magnolol on acute and inflammatory pain models in mice,” Life Sciences, vol. 81, no. 13, pp. 1071–1078, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. E. Munroe, J. L. Arbiser, and G. A. Bishop, “Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis,” The Journal of Immunology, vol. 179, no. 2, pp. 753–763, 2007. View at Google Scholar · View at Scopus
  16. S. I. Grivennikov and M. Karin, “Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer,” Cytokine and Growth Factor Reviews, vol. 21, no. 1, pp. 11–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Karin, “NF-κB and cancer: mechanisms and targets,” Molecular Carcinogenesis, vol. 45, no. 6, pp. 355–361, 2006. View at Publisher · View at Google Scholar
  18. E.-J. Park, S.-Y. Kim, Y.-Z. Zhao, and D. H. Sohn, “Honokiol reduces oxidative stress, c-jun-NH2-terminal kinase phosphorylation and protects against glycochenodeoxycholic acid-induced apoptosis in primary cultured rat hepatocytes,” Planta Medica, vol. 72, no. 7, pp. 661–664, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. M. S. Choi, S. H. Lee, H. S. Cho et al., “Inhibitory effect of obovatol on nitric oxide production and activation of NF-κB/MAP kinases in lipopolysaccharide-treated RAW 264.7cells,” European Journal of Pharmacology, vol. 556, no. 1–3, pp. 181–189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. H.-C. Ou, F.-P. Chou, W. H.-H. Sheu, S.-L. Hsu, and W.-J. Lee, “Protective effects of magnolol against oxidized LDL-induced apoptosis in endothelial cells,” Archives of Toxicology, vol. 81, no. 6, pp. 421–432, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-K. Chiang, M.-L. Sheu, Y.-W. Lin et al., “Honokiol ameliorates renal fibrosis by inhibiting extracellular matrix and pro-inflammatory factors in vivo and in vitro,” British Journal of Pharmacology, vol. 163, no. 3, pp. 586–597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J.-H. Chiu, J.-C. Wang, W.-Y. Lui, C.-W. Wu, and C.-Y. Hong, “Effect of magnolol on in vitro mitochondrial lipid peroxidation and isolated cold-preserved warm-reperfused rat livers,” Journal of Surgical Research, vol. 82, no. 1, pp. 11–16, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. M. H. Lin, H. T. Chao, and C. Y. Hong, “Magnolol protects human sperm motility against lipid peroxidation: a sperm head fixation method,” Archives of Andrology, vol. 34, no. 3, pp. 151–156, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Cui, Y. Wang, Q. Chen et al., “Magnolia extract (BL153) ameliorates kidney damage in a high fat diet-induced obesity mouse model,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 367040, 9 pages, 2013. View at Publisher · View at Google Scholar
  25. Y. K. Lee, D. Y. Yuk, T. I. Kim et al., “Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity,” Journal of Natural Medicines, vol. 63, no. 3, pp. 274–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. Y.-J. Lee, Y. M. Lee, C.-K. Lee, J. K. Jung, S. B. Han, and J. T. Hong, “Therapeutic applications of compounds in the Magnolia family,” Pharmacology and Therapeutics, vol. 130, no. 2, pp. 157–176, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Song, C. Li, and L. Cai, “Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation,” Experimental and Molecular Pathology, vol. 76, no. 1, pp. 66–75, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Zhou, C. Li, and L. Cai, “Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway,” The American Journal of Pathology, vol. 165, no. 6, pp. 2033–2043, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Zhang, Y. Tan, W. Guo et al., “Attenuation of diabetes-induced renal dysfunction by multiple exposures to low-dose radiation is associated with the suppression of systemic and renal inflammation,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 297, no. 6, pp. E1366–E1377, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. C. Faria, K. Ganesan, I. Mwangi et al., “MR imaging of liver fibrosis: current state of the art,” Radiographics, vol. 29, no. 6, pp. 1615–1635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. D. C. Rockey, “Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography,” Gastroenterology, vol. 134, no. 1, pp. 8–14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. C. C. Choong, S. K. Venkatesh, and E. P. Siew, “Accuracy of routine clinical ultrasound for staging of liver fibrosis,” Journal of Clinical Imaging Science, vol. 2, article 58, 2012. View at Publisher · View at Google Scholar
  33. V. Nobili, A. Alisi, A. Vania, C. Tiribelli, A. Pietrobattista, and G. Bedogni, “The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease,” BMC Medicine, vol. 7, article 21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. D. A. Sass, P. Chang, and K. B. Chopra, “Nonalcoholic fatty liver disease: a clinical review,” Digestive Diseases and Sciences, vol. 50, no. 1, pp. 171–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Kawano and D. E. Cohen, “Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease,” Journal of Gastroenterology, vol. 48, no. 4, pp. 434–441, 2013. View at Publisher · View at Google Scholar
  36. H.-R. Yao, J. Liu, D. Plumeri et al., “Lipotoxicity in HepG2 cells triggered by free fatty acids,” The American Journal of Translational Research, vol. 3, no. 3, pp. 284–291, 2011. View at Google Scholar · View at Scopus
  37. A. B. Goldfine, R. Silver, W. Aldhahi et al., “Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes,” Clinical and Translational Science, vol. 1, no. 1, pp. 36–43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. E. Shoelson, L. Herrero, and A. Naaz, “Obesity, inflammation, and insulin resistance,” Gastroenterology, vol. 132, no. 6, pp. 2169–2180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Fernandez-Sanchez, E. Madrigal-Santillan, M. Bautista et al., “Inflammation, oxidative stress, and obesity,” International Journal of Molecular Sciences, vol. 12, no. 5, pp. 3117–3132, 2011. View at Publisher · View at Google Scholar
  41. H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821–1830, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Furukawa, T. Fujita, M. Shimabukuro et al., “Increased oxidative stress in obesity and its impact on metabolic syndrome,” Journal of Clinical Investigation, vol. 114, no. 12, pp. 1752–1761, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Machado, P. Marques-Vidal, and H. Cortez-Pinto, “Hepatic histology in obese patients undergoing bariatric surgery,” Journal of Hepatology, vol. 45, no. 4, pp. 600–606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. R. S. Rector, J. P. Thyfault, Y. Wei, and J. A. Ibdah, “Non-alcoholic fatty liver disease and the metabolic syndrome: an update,” World Journal of Gastroenterology, vol. 14, no. 2, pp. 185–192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Lazo and J. M. Clark, “The epidemiology of nonalcoholic fatty liver disease: a global perspective,” Seminars in Liver Disease, vol. 28, no. 4, pp. 339–350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. C. P. Day, “From fat to inflammation,” Gastroenterology, vol. 130, no. 1, pp. 207–210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. S.-M. Wang, L.-J. Lee, Y.-T. Huang, J.-J. Chen, and Y.-L. Chen, “Magnolol stimulates steroidogenesis in rat adrenal cells,” British Journal of Pharmacology, vol. 131, no. 6, pp. 1172–1178, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Crum-Cianflone, A. Dilay, G. Collins et al., “Nonalcoholic fatty liver disease among HIV-infected persons,” Journal of Acquired Immune Deficiency Syndromes, vol. 50, no. 5, pp. 464–473, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. M. C. Lewis, M. L. Phillips, J. P. Slavotinek, L. Kow, C. H. Thompson, and J. Toouli, “Change in liver size and fat content after treatment with Optifast very low calorie diet,” Obesity Surgery, vol. 16, no. 6, pp. 697–701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. J. H. Ho and C. Y. Hong, “Cardiovascular protection of magnolol: cell-type specificity and dose-related effects,” Journal of Biomedical Science, vol. 19, article 70, 2012. View at Publisher · View at Google Scholar
  51. J. Li, X. Shao, L. Wu et al., “Honokiol: an effective inhibitor of tumor necrosis factor-α-induced up-regulation of inflammatory cytokine and chemokine production in human synovial fibroblasts,” Acta Biochimica et Biophysica Sinica, vol. 43, no. 5, pp. 380–386, 2011. View at Publisher · View at Google Scholar · View at Scopus